One year into the pandemic, we have moved from apprehension about the impact of COVID-19 on cancer diagnosis and treatment to concern about how cancer programs should resume full practice as the pandemic recedes. The pandemic has led to sharp drops in cancer screenings and diagnoses, and it has interrupted the ongoing treatment of many existing patients. Subsequently, some in oncology are apprehensive of a second healthcare crisis when clinics fully re-open and providers are faced with patients whose disease may have been poorly monitored due to COVID-19 restrictions.
Given the discrete regional impacts of COVID-19 and locally based vaccination efforts, cancer programs across the country are in different phases of recovery, transitioning from acute care to chronic response. The long-term impact of COVID-19 is unknown, making it necessary for cancer practices to prepare for multiple potential scenarios in the near and distant future and to gauge how those scenarios may affect different patients and their care. This project will teach multidisciplinary cancer care teams about what they should anticipate as vaccinations slowly make it possible for them to resume pre-pandemic services—specifically for patients with hematologic malignancies including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma (MM).
This education project will help cancer programs and practices transition from pre- to post-pandemic response by showcasing the solutions that have worked for practices that have successfully adapted their services to the restrictions imposed by COVID-19. To accomplish this effort, ACCC will host a webinar in which hematologic malignancy experts from various regions across the U.S. in different stages of recovery planning discuss what needs to be considered for patients with hematologic malignancies as the pandemic recedes. The webinar will be followed by three video podcasts that will juxtapose expert faculty members from regionally diverse cancer programs to highlight the differential practice implications arising from the pandemic.
Three specialists in multiple myeloma care share their experiences that may help other providers and patients move smoothly through this time of transition while maintaining high quality care.
Panelists discussed considerations for resuming pre-pandemic level visits and procedures for patients with CLL, AML, and Multiple Myeloma. Hear wins and challenges in providing care in a pandemic.
Funding & support provided by AbbVie.